Home News New Data Affecting Myopic Astigmatic Patients: NaturalVue Multifocal Demonstrates 100% Astigmatic Correction...

New Data Affecting Myopic Astigmatic Patients: NaturalVue Multifocal Demonstrates 100% Astigmatic Correction up to 2.00 D and 83% to 3.00 D

Visioneering Technologies, Inc. Highlights Astigmatism Correction and Myopia Management Advancements with NaturalVue® Multifocal at GSLS

Visioneering Technologies, Inc. maker of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, unveiled significant findings at the Global Specialty Lens Symposium (GSLS). The data is from a clinical trial led by professor Gonzalo Carracedo (Universidad Complutense de Madrid) on astigmatism correction in myopic children and updates from VTI’s ongoing PROTECT study.

ASTIGMATISM STUDY KEY FINDINGS

Presented in a poster session and a presentation titled, “Evaluation of Visual Acuity with Multifocal Catenary Curve-Based Contact Lens Design in Different Degrees of Astigmatism”:

  • Astigmatic Vision Correction:
    • 100% success with astigmatism ≤ 2.00 D.
    • 83% success with astigmatism ≤ 3.00 D.
  • Patient Experience:
    • 77% rated overall visual quality as satisfactory or better.
    • 83% rated overall comfort as satisfactory or better.
  • Additional Benefits: Preserved stereopsis and compatibility across pupil sizes.

This clinical trial validated the NaturalVue Multifocal lens astigmatism correction indication of up to 2.00 D. NaturalVue Multifocal, can correct (vs. mask) an extensive range of astigmatism by enabling both meridians to focus simultaneously due to its patented extended depth of focus design.

Dr. Ashley Tuan
Dr. Ashley Tuan

Ashley Tuan, OD, VTI’s Chief Medical Officer, says, “Professor Carracedo’s study highlights NaturalVue’s ability to provide exceptional vision while managing myopia, empowering kids to thrive without compromise.”

 

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing randomized clinical trial (RCT) studying its effectiveness for myopia progression control.

 

Read more news from WO here.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

- Advertisment -

Most Popular

New Presbyopia Resource Hub by WCO to Support Eye Care Practitioners

The World Council of Optometry (WCO) announced the launch of a new online resource hub designed to support eye care practitioners in addressing presbyopia. This...

Transitions Optical Announces Winners of the 2024 Transitions® Innovation Awards

Transitions Optical has named the winners for its annual Transitions® Innovation Awards program, which recognizes both individuals and organizations who have shown the highest...

The Spending Groove: Financial Advice for Couples

They say money can’t buy love, but it sure can cause a few arguments in the kitchen. That's why Lauretta Justin, OD, founder of...

Dr. Brianna Rhue: Don’t Forget You’re the Shark

Brianna Rhue, OD, FAAO, FSLS, seamlessly balances two roles in the optometric industry—practicing doctor and co-founder of Dr. Contact Lens, a company that provides...